Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $297.87 million. The enterprise value is $291.89 million.
Important Dates
The next confirmed earnings date is Friday, August 1, 2025, before market open.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 292.03 million shares outstanding. The number of shares has increased by 10.88% in one year.
| Current Share Class | 292.03M |
| Shares Outstanding | 292.03M |
| Shares Change (YoY) | +10.88% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 1.60% |
| Owned by Institutions (%) | 26.52% |
| Float | 287.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 63.09 |
| Forward PS | 191.50 |
| PB Ratio | 18.72 |
| P/TBV Ratio | 18.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 64.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 2.00.
| Current Ratio | 2.60 |
| Quick Ratio | 2.24 |
| Debt / Equity | 2.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -62.41 |
Financial Efficiency
Return on equity (ROE) is -248.97% and return on invested capital (ROIC) is -84.05%.
| Return on Equity (ROE) | -248.97% |
| Return on Assets (ROA) | -61.33% |
| Return on Invested Capital (ROIC) | -84.05% |
| Return on Capital Employed (ROCE) | -119.90% |
| Revenue Per Employee | $47,600 |
| Profits Per Employee | -$605,316 |
| Employee Count | 95 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.26% in the last 52 weeks. The beta is 4.19, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 4.19 |
| 52-Week Price Change | -44.26% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 49.88 |
| Average Volume (20 Days) | 7,544,016 |
Short Selling Information
The latest short interest is 63.21 million, so 21.65% of the outstanding shares have been sold short.
| Short Interest | 63.21M |
| Short Previous Month | 65.19M |
| Short % of Shares Out | 21.65% |
| Short % of Float | 22.00% |
| Short Ratio (days to cover) | 11.27 |
Income Statement
In the last 12 months, Ocugen had revenue of $4.52 million and -$57.51 million in losses. Loss per share was -$0.21.
| Revenue | 4.52M |
| Gross Profit | -27.95M |
| Operating Income | -57.04M |
| Pretax Income | -50.86M |
| Net Income | -57.51M |
| EBITDA | -54.34M |
| EBIT | -57.04M |
| Loss Per Share | -$0.21 |
Full Income StatementBalance Sheet
The company has $37.80 million in cash and $31.82 million in debt, giving a net cash position of $5.98 million or $0.02 per share.
| Cash & Cash Equivalents | 37.80M |
| Total Debt | 31.82M |
| Net Cash | 5.98M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 15.91M |
| Book Value Per Share | 0.05 |
| Working Capital | 27.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.90 million and capital expenditures -$1.05 million, giving a free cash flow of -$51.95 million.
| Operating Cash Flow | -50.90M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -51.95M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,261.43% |
| Pretax Margin | -1,271.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.88% |
| Shareholder Yield | -10.88% |
| Earnings Yield | -19.31% |
| FCF Yield | -17.44% |
Analyst Forecast
The average price target for Ocugen is $6.00, which is 488.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 488.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 185.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -6.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.21 |
| Piotroski F-Score | 2 |
